Current Agreements

Dealdoc

Licensing agreement for adeno-associated virus (AAV) vector

Renova Therapeutics
Stanford University

Dec 08 2016

Licensing agreement for adeno-associated virus (AAV) vector

Companies:	Renova Therapeutics Stanford University
Announcement date:	Dec 08 2016
Deal value, US$m:	n/d

Details

Announcement date:	Dec 08 2016
Industry sectors:	Academic Biotech
Exclusivity:	Non-exclusive
Asset type:	Technology
Therapy areas:	Cardiovascular Enabling technology
Technology types:	Gene therapy Viral vectors » Adeno-associated virus (AAV)
Deal components:	Licensing
Stages of development:	Discovery

Financials

Deal value, US$m:	n/d

Termsheet

Renova Therapeutics has obtained a nonexclusive license for a novel adeno-associated virus (AAV) vector developed in the laboratory of Professor Mark Kay, M.D., Ph.D., at Stanford University.

The company plans to use this vector in development of its paracrine gene therapy product pipeline.

Press Release

Renova Therapeutics Secures Novel AAV Vector License For Use In Metabolic And Cardiovascular Gene Therapy Development

SAN DIEGO, Dec. 8, 2016 /PRNewswire-USNewswire/ -- Renova Therapeutics, a biotechnology company developing gene therapy treatments for congestive heart failure and type 2 diabetes, announced that it has obtained a nonexclusive license for a novel adeno-associated virus (AAV) vector developed in the laboratory of Professor Mark Kay, M.D., Ph.D., at Stanford University. The company plans to use this vector in development of its paracrine gene therapy product pipeline.

"Early research has shown promise with this second-generation AAV vector for the therapeutic areas that we're pursuing," says Jack W. Reich, Ph.D., CEO and Co-founder of Renova Therapeutics. "With this agreement in place, we're able to conduct further preclinical and eventually clinical studies that are critical to advancing our pipeline."

Renova Therapeutics intends to use Dr. Kay's invention for its paracrine gene therapy program in preclinical models of various metabolic and cardiovascular diseases, including type 2 diabetes.

Renova Therapeutics' paracrine gene therapy treatments are based on a novel systemic approach that introduces therapeutic genes capable of directing the body's cells to work more normally. This proprietary approach exploits the use of peptide genes that possess favorable cardio-metabolic effects via their paracrine activity. This single-IV-injection treatment method is a foundation for future products that have the potential to bring about permanent improvements in heart failure and type 2 diabetes patients.

The company's paracrine gene therapy approach was developed by Dr. H. Kirk Hammond, Professor of Medicine, University of California, San Diego, a cardiologist at the San Diego Veterans' Affairs Healthcare System, and Co-founder of Renova Therapeutics.

About Renova Therapeutics Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

Filing Data

Not available.

Contract

Not available.